PROMOTER POLYMORPHISM -857С>T OF TNFα GENE AND EFFICACY OF ANTICYTOKINE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.15789/1563-0625-2012-1-2-81-86
Abstract
Abstract. Prevalence of TNFα gene promoter polymorphism at -857 position was investigated in normal persons and among patients with rheumatoid arthritis. We detected a relation of this polymorphism to the levels of TNFα production by mononuclear cells of healthy donors. Changes in relative frequencies of the TNFα genotypes have been shown in rheumatoid arthritis. The -857С>T polymorphism of TNFα gene proved to be informative as a molecular marker reflecting efficiency of anti-TNFα therapy in rheumatoid arthritis.
About the Authors
A. N. Silkov
НИИКИ СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
N. S. Shkaruba
НИИКИ СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
T. A. Kalashnikova
ГОУ ВПО Рост ГМУ, г. Ростов-на-Дону
Russian Federation
Russian Federation
L. P. Sizyakina
ГОУ ВПО Рост ГМУ, г. Ростов-на-Дону
Russian Federation
Russian Federation
J. B. Shulman
ГОУ ДПО СПб МАПО, Санкт-Петербург
Russian Federation
Russian Federation
S. V. Dolgikh
ГОУ ДПО СПб МАПО, Санкт-Петербург
Russian Federation
Russian Federation
V. I. Mazurov
ГОУ ДПО СПб МАПО, Санкт-Петербург
Russian Federation
Russian Federation
O. A. Gerzog
НИИКИ СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
A. E. Sizikov
НИИКИ СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
V. A. Kozlov
НИИКИ СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
S. V. Sennikov
НИИКИ СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
References
1. Алексеева Е.И., Бзарова Т.М., Валиева С.И., Алексеева А.М., Денисова Р.B., Чомахидзе A.M., Исаева К.Б., Чистякова Е.Г.Перспективы анти-TNF терапии в ревматологической практике // Вопросы современной педиатрии. – 2008. – Т. 7, № 1. – С. 56-66.
2. Насонов Е.Л. Фактор некроза опухоли-α – новая мишень для противовоспалительной терапии ревматоидного артрита // Клин. Фармакол. Терапия. – 2001. – Т. 1. – С. 64-70.
3. Breedveld F. The value of early intervention in RA--a window of opportunity // Clin. Rheumatol. – 2011. – S. 1. – P. 33-39.
4. Cuchacovich M., Ferreira L., Aliste M., Soto L., Cuenca J., Cruzat A., Gatica H., Schiattino I., Perez C., Aguirre A., Salazar-Onfray F., Aguillon J.C. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis // Scand J. Rheumatol. – 2004. – Vol. 33. – P. 228-232.
5. Haukim N., Bidwell J.L., Smith A.J., Keen L.J., Gallagher G., Kimberly R., Huizinga T., McDermott M.F., Oksenberg J., McNicholl J., Pociot F., Hardt C., D'Alfonso S. Cytokine gene polymorphism in human disease: on-line databases, supplement 2 // Genes Immun. – 2002. – Vol. 3. – P. 313-330.
6. Licastro F., Chiappelli M., Ianni M., Porcellini E. Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules // Int. J. Immunopathol. Pharmacol. – 2009. – Vol. 22. – P. 567-72.
7. Mugnier B., Balandraud N., Darque A., Roudier C., Roudier J., Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis // Arthritis Rheum. – 2003. – Vol. 48. – P. 1849-1852.
8. Nishimura M., Maeda M., Matsuoka M., Mine H., Saji H., Matsui M., Kuroda Y., Kawakami H. and Uchiyama T. Tumor necrosis factor, tumor necrosis factor receptors type 1 and 2, lymphotoxin-α, and HLA-DRB1 gene polymorphisms in human T-Cell lymphotropic virus type I associated myelopathy // Human Immunology – 2000. – Vol. 61. – P. 1262-1269.
9. Ranganathan P. Pharmacogenomics in Rheumatoid Arthritis // Pharmacogenomics in Drug Discovery and Development / Ed. Yan Q. – Humana Press. – Methods in Molecular Biology. – 2008. – Vol. 448. – P. 413-435
10. Sennikov S.V., Krysov S.V., Silkov A.N., Injelevskaya T.V., Kozlov V.A. Production of IL-10, TNF-alpha, IFN-gamma, TGF-beta1 by different populations of erythroid cells derived from human embryonal liver // Cytokine. – 2002. – Vol. 17. –P. 221-225.
11. Silva L.C., Ortigosa L.C., Benard G. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls // Immunotherapy. – 2010. – Vol. 6. –Р. 817-833.
12. Taylor P.C., Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis // Nat. Rev. Rheumatol. – 2009. –Vol. 5. – P. 578-582.
Review
For citations:
Silkov A.N., Shkaruba N.S., Kalashnikova T.A., Sizyakina L.P., Shulman J.B., Dolgikh S.V., Mazurov V.I., Gerzog O.A., Sizikov A.E., Kozlov V.A., Sennikov S.V. PROMOTER POLYMORPHISM -857С>T OF TNFα GENE AND EFFICACY OF ANTICYTOKINE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS. Medical Immunology (Russia). 2012;14(1-2):81-86. (In Russ.) https://doi.org/10.15789/1563-0625-2012-1-2-81-86
Views:
967
Email this article 